Status:
UNKNOWN
Long-term Outcome of DBS Versus Botulinum Toxin Treatment in Cervical Dystonia
Lead Sponsor:
Oslo University Hospital
Conditions:
Cervical Dystonia
Eligibility:
All Genders
18-90 years
Brief Summary
Cervical dystonia (CD) is the most common isolated dystonia in adults. Cervical dystonia symptoms can in most patients be managed well by botulinum toxin (BTX) injections, and supporting treatment mea...
Detailed Description
Cervical dystonia (CD) is the most common isolated dystonia in adults, with a prevalence of 9-13/100000. CD has a mean age at onset of 40 years, and is almost twice as common in women than in men. Cer...
Eligibility Criteria
Inclusion
- DBS-group: Patients with isolated cervical dystonia (focal or part of segmental dystonia) who have been operated at Oslo University between June 2004 and June 2017 and treated with bilateral GPi-DBS for a minimum of 3 years, and who give their informed consent to participate in this follow-up study.
- BoNT-group: Patients who are receiving regular BoNT-injections at Oslo University Hospital for isolated cervical dystonia (focal or part of segmental dystonia), who are gender-and age-matched to the operated patients, and who give their informed consent to participate in this follow-up study.
Exclusion
- Dementia/inability to respond to the CDIP-58.
Key Trial Info
Start Date :
August 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04432285
Start Date
August 6 2020
End Date
December 31 2024
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway